ArriVent BioPharma (AVBP) reported a Q3 net loss Thursday of $0.61 per diluted share, narrowing from a loss of $5.52 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.82 per share.
As expected, no revenue for the quarter ended Sept. 30 was reported.
As of Sept. 30, the clinical-stage biopharmaceutical company said it had $282.9 million in cash and cash equivalents that could fund operations into 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.